Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.49 |
| ▸ | TTR | P02766 | 2/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10414534 | 0.85 | PARP1 (0.47) | PARP1TTRPARP10PARP15TSHR | |
| SCHEMBL10414532 | 0.85 | PARP1 (0.47) | PARP1TTRPARP10PARP15TSHR | |
| SCHEMBL880074 | 0.85 | TTR (0.58) | TTRKMT2AFBP1 | |
| SCHEMBL20810556 | 0.84 | FAAH (0.46) | PARP1TSHRMEN1KMT2A | |
| SCHEMBL5329183 | 0.84 | PARP1 (0.53) | PARP1PARP10PARP15TSHRPARP14 | |
| SCHEMBL14292511 | 0.83 | KDM1A (0.39) | TTRPTGS1PTGS2FBP1HDAC3 | |
| SCHEMBL13699040 | 0.83 | PARP1 (0.45) | PARP1TTR | |
| SCHEMBL7615559 | 0.81 | PARP1 (0.53) | PARP1TTRPARP10PARP15TSHR | |
| SCHEMBL10881897 | 0.81 | HPGD (0.42) | TTRTSHRFBP1HDAC3HDAC1 | |
| SCHEMBL14604961 | 0.81 | P4HB (0.58) | TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589067-B2 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | CYP2B6, CYP2D6, ABCB11 | PARP1 3253/4885TTR 4451/4885PARP10 2573/4885 |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ABCB11, ABCB1, CYP2B6 | PARP1 4713/4885TTR 2094/4885PARP10 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.